李爱新,王爱芝,李在村,邵英,叶江竹,孙丽君

• 1:首都医科大学附属北京佑安医院感染中心

摘要(Abstract)：

目的探讨依非韦伦(EFV)更换为洛匹那韦/利托那韦(LPV/r)后,对艾滋病(AIDS)病人睡眠障碍、焦虑和抑郁症状(SAD症状)的影响情况。方法共62例AIDS病人,用统一的调查问卷收集社会人口学资料和用药情况,用匹兹堡睡眠质量指数量表(PSQI)、医院焦虑抑郁情绪测量表(HAD量表),调查病人SAD症状的变化情况。结果 62例中,男性占98.39%,平均年龄(32.84±8.54)岁,大专及以上文化占72.58%,同性性传播占75.81%,更换抗病毒治疗方案的前三位原因依次为中枢神经系统症状(70.97%)、皮疹(9.68%)、一线治疗失败(8.06%)。62例AIDS病人基线平均PSQI值为(8.19±3.90)分,医院焦虑抑郁情绪测量表焦虑评分(HAD-A)为(6.32±4.52)分,抑郁评分(HAD-D)为(6.40±4.91)分。换用LPV/r 3个月后分别为(6.56±2.97)分、(5.27±3.58)分和(5.58±4.76)分(P值分别为0.000、0.029和0.081)。基线时PSQI、HAD-A和HAD-D评分>7分的病人分别占48.39%、38.71%和43.55%,换药3个月分别为35.48%、27.42%和32.26%(P值分别为0.001、0.002和0.000)。结论经治AIDS病人中,含EFV抗病毒治疗方案存在神经精神相关不良反应,即不同程度的睡眠障碍及焦虑、抑郁症状,是导致更换治疗方案的主要原因。治疗方案更换为LPV/r的组合后,病人SAD症状较前明显改善。

关键词(KeyWords)： 艾滋病病人;抗病毒药物;睡眠障碍;焦虑;抑郁

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李爱新,王爱芝,李在村,邵英,叶江竹,孙丽君

DOI: 10.13419/j.cnki.aids.2017.09.04

参考文献(References)：

• [1]Cohen J.Breakthrough of the year.HIV treatment as prevention[J].Science,2011,334(6063):1628.
• [2]Deeks SG,Lewin SR,Havlir DV.The end of AIDS:HIV infection as a chronic disease[J].Lancet,2013,382(9903):1525-1533.
• [3]江英骙,薛以乐,蒋卫民,等.影响艾滋病患者治疗依从性的因素及干预措施[J].中华传染病杂志,2015,33(9):572-574.
• [4]中华医学会精神科分会.中国精神障碍分类与诊断标准[M].3版(CCMD-3).济南:山东科学技术出版社,2001.
• [5]Gamaldo CE,Spira AP,Hock RS,et al.Sleep,function and HIV:a multi-method assessment[J].AIDS Behav,2013,17(8):2808-2815.
• [6]Low Y,Goforth H,Preud'Homme X,et al.Insomnia in HIV-infected patients:pathophysiologic implications[J].AIDS Rev,2014,16(1):3-13.
• [7]Chen WT,Shiu CS,Yang JP,et al.Fatigue and Sleep Disturbance Related to Perceived Stress in Chinese HIV-Positive Individuals:A Mixed Methods Study[J].J AIDS Clin Res,2013,4(6):26.
• [8]Chen WT,Shiu CS,Yang JP,et al.Antiretroviral Therapy(ART)Side Effect Impacted on Quality of Life,and Depressive Symptomatology:A Mixed-Method Study[J].J AIDS Clin Res,2013,4:218.
• [9]Taibi DM.Sleep disturbances in persons living with HIV[J].J Assoc Nurses AIDS Care,2013,24(1 Suppl):S72-S85.
• [10]Carter MW,Kraft JM,Hatfield-Timajchy K,et al.The reproductive health behaviors of HIV-infected young women in the United States:A literature review[J].AIDS Patient Care STDS,2013,27(12):669-680.
• [11]Abers MS,Shandera WX,Kass JS.Neurological and psychiatric adverse effects of antiretroviral drugs[J].CNS Drugs,2014,28(2):131-145.
• [12]Raffi F,Pozniak AL,Wainberg MA.Has the time come to abandon efavirenz for first-line antiretroviral therapy[J].J Antimicrob Chemother,2014,69(7):1742-1747.
• [13]Mothapo KM,Schellekens A,van Crevel R,et al.Improvement of Depression and Anxiety After Discontinuation of Long-Term Efavirenz Treatment[J].CNS Neurol Disord Drug Targets,2015,14(6):811-818.
• [14]Leutscher PD,Stecher C,Storgaard M,et al.Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects[J].Scand J Infect Dis,2013,45(8):645-651.
• [15]AIDSinfo.Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents[EB/OL].U.S.Department of Health and Human Services,July 14,2016.http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0.
• [16]Capparelli EV,Holland D,Okamoto C,et al.Lopinavir concentrations in cerebrospinal fluid exceed the 50%inhibitory concentration for HIV[J].AIDS,2005,19(9):949-952.
• [17]Hammond ER,Crum RM,Treisman GJ,et al.The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV[J].Am J Epidemiol,2014,180(3):297-307.